Monthly webinar series
In this online seminar series, we review the biological principles behind different immunotherapies and how measuring cell avidity can be used as a functional biomarker to help fundamentally improve cell therapy development.
The power of innate immune cells to improve cancer immunotherapies
NEW In this webinar, Dr Julian Ashby will be:
– Deep diving into Natural Killer (NK) cell biology and therapies
– Evaluating the advantages of allogeneic cell therapies
– Highlighting Cell Avidity as a key indicator of therapeutic performance for NK, CAR-NK, gamma delta T cells and macrophages
Time and Date
Thursday, 8 December at 3:00 PM CET/ 8:00 AM CT/ 9:00 AM ET / 9:00 PM CST
Dr. Julian Ashby, Field Application Scientist from LUMICKS
Keynote speaker webinars
Seminars from world-leading experts
Don’t miss world-renowned researchers talk about their experience with cell avidity measurements for T cell functionality prediction.
Cell Avidity Measurements to Understand and Enhance CAR-T/Tumor InteractionsWatch this webinar to learn about novel CARs and the use of avidity measurements to understand and enhance productive CAR-T cell interactions with both liquid and solid tumors from Dr. Marcela Maus, Director of cellular immunotherapy at Harvard Medical school.
Cell avidity as a crucial biomarker for CAR T response
Dr. Rebecca Larson presented her work on “Loss of IFNγR signaling and downstream adhesion confers resistance to CAR T cell cytotoxicity in solid but not liquid tumors” in Nature. Learn how cell avidity measurements can improve CAR T cell response in solid tumors by identifying important evasion mechanism.
CAR T-Cell Immunotherapy of Solid Tumors – Learning from the Clinic and Lab in Parallel
Learn about Leucid Bio’s efforts in developing a next-generation CAR platform, known as parallel (p)CAR. In this webinar, Dr. John Maher demonstrated how to use the z-Movi to address the importance of relative binding affinity in the design of optimized pCAR?
Combining a CAR and a chimeric costimulatory receptor enhances T-cell sensitivity to low antigen density and promotes persistence
Learn from Dr. Maria Themeli how to overcome low antigen density and improve CAR-T cell persistence with multi-targeting and co-stimulation through increasing synaptic avidity with the z-Movi.
Exploring the network of cellular interactions of NK cells in the tumor microenvironment
Learn from Prof. Lowdell how primed NK cells become effective against resistant tumor cells, and how cell avidity measurements were used to depict a stronger binding of primed NK cells, resulting in improved tumor cell killing.
Dual-targeted cell therapy targeting BCMA and GPRCD5 to prevent relapse in multiple myeloma
Learn from Prof. de Larrea how expressing two CARs on a single cell enhances the strength of CAR T-cell/target cell interactions, prevents BCMA escape-driven relapse, and how cell avidity measurements contributed to their findings.
Deep-dive into the applications with LUMICKS’ scientists
Watch our webinars presented by expert speakers, covering the latest breakthroughs and developments in immuno-oncology.
Explore experiments across the topics of CAR-T cells, TCR T cells, NK cells, and bispecific antibody-engaged T cells, showing a correlation between avidity and T cell functionality.
Discover how measuring cellular avidity using the z-Movi Cell Avidity Analyzer helps researchers to quickly identify optimal functioning CARs and compare between panels.
How does the z-Movi Cell Avidity Analyzer measure cell avidity? Why does avidity matter in TCR-dependent T-cell cytotoxicity? How does it compare with functional assays?
We present avidity data, obtained by Dr. Nathalie Rufer’s research team at the University of Lausanne, showing a linear correlation between T cell function and cell avidity.
Watch past webinars
Download the video recording and slide deck of past webinars
Fill in the form below to watch previously-held webinars on-demand. If you miss something don’t hesitate to let us know!